Galera Therapeutics, Inc. (GRTX) Financials
Newest figures come from the 10-Q for Q1 FY2026, filed May 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GRTX SEC filings page.
This page shows Galera Therapeutics, Inc. (GRTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Liability reduction and development-spending contraction have reshaped Galera faster than its cash-generating operations have.
From FY2023 to FY2025, the operating loss narrowed from-$49.3M to-$2.5M while R&D fell from$24.1M to$349K ; the parallel improvement therefore reflects a much smaller development program more than demonstrated commercial scaling. In FY2025, operating cash flow remained negative at-$6.0M despite the operating loss of-$2.5M , so reduced accounting losses have not yet translated into self-funding operations.
Equity moved from
A current ratio of 11.0x and 12.6 months of reported liquidity indicate that short-term obligations were small relative to reported liquid resources at FY2025 year-end. However, financing inflow of
Financial Health Signals
Galera Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Galera Therapeutics, Inc. reported -$1.6M in net income in Q1 2026. This represents a decrease of 0.9% from the same quarter a year earlier.
Not reported for Q1 2026.
Not reported for Q1 2026.
Cash & Balance Sheet
Galera Therapeutics, Inc. held $5.5M in cash as of Q1 2026; long-term debt is not reported for that period.
Not reported for Q1 2026.
Not reported for Q1 2026.
Margins & Returns
Galera Therapeutics, Inc.'s ROE was -220.6% in Q1 2026, measuring profit generated per dollar of shareholder equity.
Not reported for Q1 2026.
Not reported for Q1 2026.
Not reported for Q1 2026.
Capital Allocation
Galera Therapeutics, Inc. invested $15K in research and development in Q1 2026. This represents a decrease of 83.9% from the same quarter a year earlier.
Not reported for Q1 2026.
Not reported for Q1 2026.
GRTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $15K-83.9% | N/A | $130K-57.4% | $84K-94.1% | $93K-93.8% | N/A | $305K-95.0% | $1.4M-81.1% |
| SG&A Expenses | $1.6M-12.3% | N/A | $1.3M-62.0% | $1.1M-62.2% | $1.9M-39.5% | N/A | $3.4M-31.1% | $2.8M-69.9% |
| Operating Income | -$1.7M+15.7% | N/A | -$1.4M+75.7% | -$1.1M+73.0% | -$2.0M+57.1% | N/A | -$5.9M+55.9% | -$4.2M+75.0% |
| EBITDA | N/A | N/A | -$1.4M+75.7% | -$1.1M+73.0% | -$2.0M+57.0% | N/A | -$5.9M+55.9% | -$4.2M+75.0% |
| Interest Expense | $0 | N/A | $0 | N/A | $0 | N/A | $0-100.0% | $0-100.0% |
| Income Tax | N/A | N/A | $0+100.0% | N/A | N/A | N/A | -$203K | N/A |
| Net Income | -$1.6M-0.9% | N/A | -$1.4M+75.1% | -$1.1M+73.5% | -$1.6M+63.7% | N/A | -$5.6M+63.0% | -$4.1M+80.4% |
| EPS (Basic) | -$0.010.0% | $0.66+925.0% | -$0.01+90.0% | $0.00+100.0% | -$0.01+87.5% | -$0.08-166.7% | -$0.10+69.7% | -$0.07+85.4% |
| EPS (Diluted) | -$0.01 | $0.66+925.0% | -$0.01 | $0.00+100.0% | -$0.01 | -$0.08-166.7% | -$0.10+69.7% | -$0.07+85.4% |
| Diluted Shares (Avg) | 99M | N/A | 99M | 99M+81.1% | 99M | N/A | 54M+19.6% | 54M+26.7% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
GRTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.2M-19.5% | $7.2M-28.8% | $5.0M-43.8% | $6.0M-63.1% | $7.7M-61.0% | $10.1M-61.4% | $8.9M-76.4% | $16.4M-66.1% |
| Current Assets | $6.1M-19.8% | $7.1M-29.1% | $4.9M-44.9% | $5.9M-50.3% | $7.6M-50.2% | $10.0M-53.8% | $8.9M-71.5% | $12.0M-71.5% |
| Cash & Equivalents | $5.5M-17.7% | $6.4M-23.1% | $4.5M-47.1% | $5.2M-51.3% | $6.7M-50.3% | $8.3M-54.6% | $8.5M-65.3% | $10.7M-55.8% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0-100.0% | $0-100.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $0-100.0% | $881K0.0% |
| Total Liabilities | $5.4M-96.5% | $3.2M-98.0% | $154.2M+1.5% | $154.0M-0.3% | $154.9M+0.4% | $158.1M+0.5% | $152.0M-7.5% | $154.4M-5.4% |
| Current Liabilities | N/A | $645K-61.3% | $598K-34.6% | $347K-83.7% | $975K-51.6% | $1.7M-66.4% | $914K-92.8% | $2.1M-84.4% |
| Non-Current Liabilities | N/A | $2.6M-98.4% | $153.6M+1.7% | $153.6M+0.9% | $153.9M+1.0% | $156.5M+2.7% | $151.0M-0.4% | $152.3M+1.8% |
| Total Equity | $728K+100.5% | $4.0M+102.7% | -$149.2M-4.3% | -$147.9M-7.2% | -$147.2M-9.3% | -$148.0M-12.8% | -$143.1M-13.0% | -$138.0M-20.0% |
| Retained Earnings | -$308.9M+32.5% | -$307.3M+32.7% | -$460.4M-2.0% | -$459.0M-3.0% | -$458.0M-3.7% | -$456.4M-4.3% | -$451.4M-4.5% | -$445.9M-7.0% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.
GRTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$875K+60.9% | -$1.6M+31.7% | -$757K+67.1% | -$1.5M+46.4% | -$2.2M+53.3% | -$2.3M+76.4% | -$2.3M+81.6% | -$2.7M+74.7% |
| Depreciation & Amortization | N/A | $0 | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $5K-58.3% | $6K-50.0% |
| Stock-Based Compensation | $78K-43.1% | N/A | $91K-83.5% | $90K-87.6% | $137K-84.3% | N/A | $551K-60.4% | $723K-52.6% |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $0 | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | -$2.3M+76.4% | -$2.3M+81.6% | N/A |
| Investing Cash Flow | N/A | $3.5M+7100.0% | N/A | N/A | N/A | -$50K-101.3% | $4K-100.0% | $0-100.0% |
| Financing Cash Flow | $0-100.0% | $0-100.0% | $0 | $0 | $635K | $2.2M+1058.2% | $0-100.0% | $0-100.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
GRTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -220.6% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -26.1%-5.3pp | N/A | -27.8%+34.9pp | -17.8%+7.0pp | -20.8%+1.5pp | N/A | -62.7%-22.8pp | -24.8%+18.1pp |
| Current Ratio | N/A | 11.00+5.0x | 8.20-1.5x | 17.14+11.5x | 7.75+0.2x | 6.00+1.6x | 9.74+7.3x | 5.63+2.5x |
| Debt-to-Equity | 7.47 | 0.81 | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Galera Therapeutics, Inc. GRTX | FY2025 | N/A | N/A | N/A | N/A | — |
| Ocean Biomedical Inc. OCEA | FY2024 | N/A | N/A | N/A | $6.8M | — |
| Vaccinex Inc VCNX | FY2024 | $601K | N/A | N/A | $2.8M | — |
| Ayala Pharm ADXS | FY2023 | $13K | -$48.1M | N/A | $25.7M | — |
| Axim Biotechnologies Inc AXIM | FY2023 | $40K | -$8.1M | N/A | $1.7M | — |
| Regen Biopharma RGBPP | FY2025 | $237K | -$1.3M | N/A | N/A | — |
Where Galera Therapeutics, Inc. Ranks
Frequently Asked Questions
What is Galera Therapeutics, Inc.'s EBITDA?
Galera Therapeutics, Inc. (GRTX) had EBITDA of -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Galera Therapeutics, Inc.'s operating cash flow?
Galera Therapeutics, Inc. (GRTX) recorded an outflow of $6.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Galera Therapeutics, Inc.'s total assets?
Galera Therapeutics, Inc. (GRTX) had $7.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Galera Therapeutics, Inc. spend on research and development?
Galera Therapeutics, Inc. (GRTX) invested $349K in research and development during fiscal year 2025.
What is Galera Therapeutics, Inc.'s current ratio?
Galera Therapeutics, Inc. (GRTX) had a current ratio of 11.00 as of fiscal year 2025, which is generally considered healthy.
What is Galera Therapeutics, Inc.'s debt-to-equity ratio?
Galera Therapeutics, Inc. (GRTX) had a debt-to-equity ratio of 0.81 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
How does Galera Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Galera Therapeutics, Inc. (GRTX) held $6.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $6.0M over that year. Dividing the one by the other, the reported balance equals about 13 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.